Clinical Trial Update: FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing FAC vs FAC plus weekly paclitaxel as adjuvant treatment in node-negative high-risk breast cancer; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FAC (FAC (fluorouracil, doxorubicin, cyclophosphamide))
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-07-12